| Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study. | |
| | |
MedLine Citation:
|
PMID: 20649627 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
AIM: To determine whether combination of metformin-sulphonylurea is associated with an increased risk of cardiovascular disease (CVD) and mortality in an urban community-based cohort of type 2 patients. METHODS: We studied 1271 (98.2%) of 1294 type 2 participants in the observational Fremantle Diabetes Study (mean age 64.2 years, 48.8% males) who had detailed diabetes-specific therapy recorded at baseline and complete follow-up data. Mortality and hospital discharge data were collected over 13 174 patient-years (mean +/- SD: 10.4 +/- 3.9 years). Cox proportional hazards modelling was used to determine whether baseline diabetes treatments were independently associated with cardiovascular mortality, hospitalization for/death from CVD or all-cause mortality after adjustment for other explanatory variables. RESULTS: During follow-up, 523 deaths occurred (41.1%) of which 269 (51.4%) were attributed to CVD. Hospitalization for CVD as principal diagnosis occurred at least once for 481 (37.8%) participants. In Kaplan-Meier analyses, there were significant differences in cardiovascular mortality, hospitalization for/death from CVD and all-cause mortality between diabetes therapy groups (p < 0.001). Compared with diet and metformin monotherapy, those treated with metformin-sulphonylurea had higher cardiovascular and all-cause mortality (p < or = 0.024). Insulin users had significantly higher cardiovascular mortality, hospitalization for/death from CVD and all-cause mortality than those on combination therapy (p < or = 0.016). After adjustment for significant variables in the most parsimonious models, diabetes treatment was not independently associated with any of the three study endpoints (p > or = 0.49). CONCLUSIONS: Combination metformin-sulphonylurea appears as safe as other blood glucose-lowering therapies used for type 2 diabetes. |
| | |
Authors:
|
B Sillars; W A Davis; I B Hirsch; T M E Davis |
Related Documents
:
|
12738397 - Lipoprotein(a), apolipoprotein(a) polymorphism and restenosis after intracoronary stent... 1079397 - Aortocoronary bypass in the diabetic patient. 2347437 - Prognosis after stroke in diabetic patients. a controlled prospective study. 9174897 - Characteristics, clinical course, and in-hospital mortality of non-insulin-dependent di... 15701217 - Fine-tuning therapy with basal insulin for optimal glycemic control in type 2 diabetes:... 7131637 - Salicylate ototoxicity in the chinchilla: a behavioral and electron microscope study. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Diabetes, obesity & metabolism Volume: 12 ISSN: 1463-1326 ISO Abbreviation: Diabetes Obes Metab Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-07-23 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883645 Medline TA: Diabetes Obes Metab Country: England |
Other Details:
|
Languages: eng Pagination: 757-65 Citation Subset: IM |
Affiliation:
|
University of Western Australia, Nedlands, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low...
Next Document: Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those w...